|
rs878854066
|
|
|
0.020 |
GeneticVariation |
BEFREE |
R72P associations with specific cancer risk, particularly hematological malignancies, have been conflicting.
|
25768405 |
2015 |
|
rs878854066
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The overall results suggested that p53 Arg72Pro polymorphism was not associated with hematological malignancies risk.
|
23029260 |
2012 |
|
rs104894226
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
|
rs1057519766
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three out of 14 (21.4 %) C57BL/6J mice transplanted with FLT3-N676K-transduced primary hematopoietic progenitor cells developed acute leukemia (latency of 68, 77, and 273 days), while no hematological malignancy was observed in the control groups including FLT3-ITD.
|
26891877 |
2016 |
|
rs1057520009
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Recent reports have shown molecular alterations in the gene encoding XPO1 and showed a mutation hotspot (E571K) in the following two hematological malignancies with similar phenotypes and natural histories: primary mediastinal diffuse large B cell lymphoma and classical Hodgkin's lymphoma.
|
28196522 |
2017 |
|
rs1114167651
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Wild type SHP-2 and four disease-associated mutants recurring in hematologic malignancies (Glu76Lys and Ala72Val) or causing NS (Glu76Asp and Ala72Ser), with affected residues located in the PTP-interacting region of the N-SH2 domain, were analyzed by molecular dynamics simulations and in vitro biochemical assays.
|
17177198 |
2007 |
|
rs112445441
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
|
rs11536889
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We retrospectively examined whether or not genetic variations in toll-like receptor 1 (rs5743551, -7202GQ>A), toll-like receptor 2 (rs7656411, 22215G>T), and toll-like receptor 4 (rs11536889, +3725G>C) affected transplant outcomes in a cohort of 365 patients who underwent unrelated HLA-matched bone marrow transplantation (for hematologic malignancies through the Japan Marrow Donor Program.
|
28484092 |
2017 |
|
rs121434596
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
|
rs121913507
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The findings also suggest that targeting the SPHK/S1P axis may provide an alternative to tyrosine kinase inhibitors, alone or in combination, for the treatment of aggressive mastocytosis and other hematological malignancies associated with the D816V-KIT mutation.
|
29643855 |
2018 |
|
rs121913682
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The findings also suggest that targeting the SPHK/S1P axis may provide an alternative to tyrosine kinase inhibitors, alone or in combination, for the treatment of aggressive mastocytosis and other hematological malignancies associated with the D816V-KIT mutation.
|
29643855 |
2018 |
|
rs121918453
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Wild type SHP-2 and four disease-associated mutants recurring in hematologic malignancies (Glu76Lys and Ala72Val) or causing NS (Glu76Asp and Ala72Ser), with affected residues located in the PTP-interacting region of the N-SH2 domain, were analyzed by molecular dynamics simulations and in vitro biochemical assays.
|
17177198 |
2007 |
|
rs121918454
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Wild type SHP-2 and four disease-associated mutants recurring in hematologic malignancies (Glu76Lys and Ala72Val) or causing NS (Glu76Asp and Ala72Ser), with affected residues located in the PTP-interacting region of the N-SH2 domain, were analyzed by molecular dynamics simulations and in vitro biochemical assays.
|
17177198 |
2007 |
|
rs121918464
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Wild type SHP-2 and four disease-associated mutants recurring in hematologic malignancies (Glu76Lys and Ala72Val) or causing NS (Glu76Asp and Ala72Ser), with affected residues located in the PTP-interacting region of the N-SH2 domain, were analyzed by molecular dynamics simulations and in vitro biochemical assays.
|
17177198 |
2007 |
|
rs1239105602
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Wild type SHP-2 and four disease-associated mutants recurring in hematologic malignancies (Glu76Lys and Ala72Val) or causing NS (Glu76Asp and Ala72Ser), with affected residues located in the PTP-interacting region of the N-SH2 domain, were analyzed by molecular dynamics simulations and in vitro biochemical assays.
|
17177198 |
2007 |
|
rs13347
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, our results indicate that among investigated single nucleotide polymorphisms (SNPs), only CD44 rs13347 has an impact on the efficacy of HSCs mobilization in patients with hematologic malignancies.
|
24680978 |
2014 |
|
rs148704956
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This study retrospectively examined the impact of a single-nucleotide polymorphism (rs2275913, G197A) in the IL-17 gene of a total 510 recipients with hematologic malignancies and their unrelated donors on the clinical outcomes in HLA-matched myeloablative (discovery study) and nonmyeloablative (validation study) BMT through the Japan Marrow Donor Program (JMDP).
|
21217785 |
2011 |
|
rs1799782
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The current meta-analysis indicated that the Arg194Trp polymorphism in the XRCC1 gene might be not a risk factor for hematological malignancies.
|
24414482 |
2014 |
|
rs1800023
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We retrospectively examined the impact of the CCR5 variation (rs1800023, -2086A>G) on transplant outcomes in a cohort of 329 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program.
|
28487238 |
2017 |
|
rs1801157
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Several recent studies have shown that <i>SDF1</i>-3'A polymorphism (rs1801157) is associated with susceptibility to hematological malignancy, but published studies' results are disputed.
|
28352190 |
2017 |
|
rs2229094
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Subgroup meta-analysis suggested that rs2239704 was likely to increase the risk of hematological malignancy (OR = 1.10, 99% CI = 1.01-1.20, P = 0.023, I(2) = 0.0%), and rs2229094 was specific for the increased risk of adenocarcinoma (OR = 1.33, 99% CI = 1.11-1.59, P = 0.002, I(2) = 0.0%).
|
24349304 |
2013 |
|
rs2239704
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Subgroup meta-analysis suggested that rs2239704 was likely to increase the risk of hematological malignancy (OR = 1.10, 99% CI = 1.01-1.20, P = 0.023, I(2) = 0.0%), and rs2229094 was specific for the increased risk of adenocarcinoma (OR = 1.33, 99% CI = 1.11-1.59, P = 0.002, I(2) = 0.0%).
|
24349304 |
2013 |
|
rs2285489
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We retrospectively examined whether <i>ADAMTS13</i> rs2285489 affected the transplant outcomes in a cohort of 281 patients who underwent unrelated human leukocyte antigen (HLA)-matched bone marrow transplantation for hematologic malignancies.
|
30626079 |
2019 |
|
rs25487
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The current meta-analysis indicated that the Arg399Gln polymorphism in the XRCC1 gene might be a risk factor for hematological malignancies in Asians or for leukemia.
|
25619474 |
2015 |
|
rs25489
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The current meta-analysis indicated that the Arg280His polymorphism in the XRCC1 gene might not be a risk factor for hematological malignancies.
|
24096581 |
2014 |